Bio-Techne revenue
Bio-Techne's revenue was $1.22bn in fiscal 2026, down 0.4% on the year before. Since fiscal 2010 ($269m) it has grown at a compound 9.9% a year.
Revenue history
| Fiscal year | 2010Jun 2010 | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269 | 290 | 315 | 311 | 358 | 452 | 499 | 563 | 643 | 714 | 739 | 931 | 1,106 | 1,137 | 1,159 | 1,220 | 1,215 |
| Growth on the year before | — | +7.8% | +8.5% | −1.3% | +15.2% | +26.4% | +10.3% | +12.8% | +14.2% | +11.0% | +3.5% | +26.0% | +18.7% | +2.8% | +2.0% | +5.2% | −0.4% |
| Gross profit | 214 | 225 | 236 | 231 | 251 | 307 | 337 | 375 | 432 | 473 | 483 | 633 | 756 | 770 | 770 | 790 | 799 |
| Gross margin | 79.6% | 77.6% | 75.0% | 74.4% | 70.3% | 67.9% | 67.5% | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Product and Services | $1.2B | 97.9% | ▼ 0.5% |
| Consumables (part of Product and Services) | $985M | 82.8% | ▲ 1.3% |
| Instruments (part of Product and Services) | $111M | 9.3% | ▼ 1.3% |
| Services (part of Product and Services) | $94.3M | 7.9% | ▼ 15.5% |
| Royalty | $25M | 2.1% | ▲ 5.5% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $635M | 52.3% | ▼ 7.0% |
| EMEA Excluding UK | $294M | 24.2% | ▲ 10.5% |
| China | $104M | 8.6% | ▲ 3.6% |
| APAC Excluding Greater China | $85.8M | 7.1% | ▲ 11.1% |
| United Kingdom | $56.3M | 4.6% | ▲ 2.7% |
| Rest of World | $39.3M | 3.2% | ▲ 4.6% |
From Bio-Techne's 10-K filed August 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Bio-Techne | $1.22bn | -0.4% | 2.2% |
| Sotera Health Co | $1.22bn | 8.1% | 7.6% |
| Repligen Corp | $806m | 13.8% | 7.3% |
| Neogenomics Inc | $788m | 11.1% | 11.1% |
| Qiagen N.V. | $2.09bn | 5.7% | 17.1% |
| 10x Genomics, Inc. | $617m | -4.3% | 2.8% |
Compare with peers
- Sotera Health Co revenue
- Repligen Corp revenue
- Neogenomics Inc revenue
- Qiagen N.V. revenue
- 10x Genomics, Inc. revenue
Head to head: SHC vs TECHRGEN vs TECHNEO vs TECH
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies